{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:18:38Z","timestamp":1773368318926,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008331","name":"Universidade Federal do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pep.2025.106841","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:29:00Z","timestamp":1763029740000},"page":"106841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative biophysical and functional analysis of TCZ-UFRJ, a potential biosimilar to Actemra"],"prefix":"10.1016","volume":"239","author":[{"given":"Sanclayver","family":"Corr\u00eaa Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico Francisco","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Guimar\u00e3es Alvim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia Maria","family":"dos Santos Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heitor Affonso","family":"de Paula Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yraima","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcius","family":"da Silva Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leda","family":"dos Reis Castilho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2530-752X","authenticated-orcid":false,"given":"Renato","family":"Sampaio Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pep.2025.106841_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrcardio.2015.51","article-title":"Assessing the efficacy and safety of evolocumab and alirocumab","author":"Huynh","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.pep.2025.106841_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pep.2025.106841_bib3","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.pep.2025.106841_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.pep.2025.106841_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1742-7843.2009.00452.x","article-title":"Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis","volume":"106","author":"Korhonen","year":"2010","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.pep.2025.106841_bib6","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2214-109X(22)00460-0","article-title":"Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities","volume":"11","author":"Morin","year":"2023","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.pep.2025.106841_bib7","article-title":"Public policy coverage and access to medicines in Brazil","volume":"56","author":"de Moraes","year":"2022","journal-title":"Rev. Saude Publica"},{"key":"10.1016\/j.pep.2025.106841_bib8","series-title":"Purchase of Medicines by the Brazilian Federal Government","author":"de Negri","year":"2023"},{"key":"10.1016\/j.pep.2025.106841_bib9","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1590\/1413-81232021269.2.31962019","article-title":"The public production of medicines in Brazil","volume":"26","author":"Figueiredo","year":"2021","journal-title":"Ci\u00eancia Sa\u00fade Coletiva"},{"key":"10.1016\/j.pep.2025.106841_bib10","first-page":"1s","article-title":"Availability of essential medicines in primary health care of the Brazilian unified Health System","volume":"51","author":"do Nascimento","year":"2017","journal-title":"Rev. Saude Publica"},{"key":"10.1016\/j.pep.2025.106841_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.dmpk.2018.11.004","article-title":"Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies","volume":"34","author":"Ishii-Watabe","year":"2019","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.pep.2025.106841_bib12","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.3.6.17922","article-title":"The impact of glycosylation on monoclonal antibody conformation and stability","volume":"3","author":"Zheng","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.pep.2025.106841_bib13","series-title":"Adv Exp Med Biol","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4615-0685-0_7","article-title":"The molecular specificity of IgG-Fc interactions with Fc\u03b3 receptors","author":"Mimura","year":"2001"},{"key":"10.1016\/j.pep.2025.106841_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2022.339828","article-title":"N-Glycosylation of monoclonal antibody therapeutics: a comprehensive review on significance and characterization","volume":"1209","author":"Shrivastava","year":"2022","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.pep.2025.106841_bib15","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4049\/jimmunol.1502136","article-title":"The emerging importance of IgG Fab Glycosylation in immunity","volume":"196","author":"van de Bovenkamp","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.pep.2025.106841_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2019.00472","article-title":"High level production of monoclonal antibodies using an optimized plant expression system","volume":"7","author":"Diamos","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.pep.2025.106841_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pep.2025.106841_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00253-004-1656-9","article-title":"Recombinant expression systems in the pharmaceutical industry","volume":"65","author":"Schmidt","year":"2004","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.pep.2025.106841_bib19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/nbt1026","article-title":"Production of recombinant protein therapeutics in cultivated Mammalian cells","volume":"22","author":"Wurm","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.pep.2025.106841_bib20","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1023\/A:1015894409623","article-title":"Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping","volume":"9","author":"Kroon","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.pep.2025.106841_bib21","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1021\/ac991444k","article-title":"Thermal denaturation: a useful technique in peptide mass mapping","volume":"72","author":"Park","year":"2000","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib22","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1002\/jctb.5682","article-title":"Higher-order structure and conformational change in biopharmaceuticals","volume":"93","author":"Orphanou","year":"2018","journal-title":"J. Chem. Technol. Biotechnol."},{"key":"10.1016\/j.pep.2025.106841_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jrs.4335","article-title":"Raman spectroscopy of proteins: a review","volume":"44","author":"Rygula","year":"2013","journal-title":"J. Raman Spectrosc."},{"key":"10.1016\/j.pep.2025.106841_bib24","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/nprot.2006.202","article-title":"Using circular dichroism spectra to estimate protein secondary structure","volume":"1","author":"Greenfield","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.pep.2025.106841_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389203003381315","article-title":"The use of circular dichroism in the investigation of protein structure and function","volume":"1","author":"Kelly","year":"2000","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.pep.2025.106841_bib26","series-title":"Principles of Fluorescence Spectroscopy","first-page":"530","article-title":"Protein fluorescence","author":"Lakowicz","year":"2006"},{"key":"10.1016\/j.pep.2025.106841_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jctb.4850","article-title":"Protein deamidation in biopharmaceutical manufacture: understanding, control and impact","volume":"91","author":"Gervais","year":"2016","journal-title":"J. Appl. Chem. Biotechnol."},{"key":"10.1016\/j.pep.2025.106841_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.drudis.2018.01.009","article-title":"On the glycosylation aspects of biosimilarity","volume":"23","author":"Hajba","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.pep.2025.106841_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ab.2005.10.009","article-title":"Infrared spectroscopy used to evaluate glycosylation of proteins","volume":"348","author":"Khajehpour","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.pep.2025.106841_bib30","doi-asserted-by":"crossref","first-page":"11509","DOI":"10.1021\/acs.analchem.5b03291","article-title":"Collision induced unfolding of intact antibodies: rapid characterization of disulfide bonding patterns, glycosylation, and structures","volume":"87","author":"Tian","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib31","series-title":"Aggregation of Therapeutic Proteins","first-page":"205","article-title":"Experimental detection and characterization of protein aggregates","author":"Sharma","year":"2010"},{"key":"10.1016\/j.pep.2025.106841_bib32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jps.23839","article-title":"Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions","volume":"103","author":"Telikepalli","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pep.2025.106841_bib33","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/jps.24509","article-title":"Selective oxidation of methionine and tryptophan residues in a therapeutic IgG1 molecule","volume":"104","author":"folzer","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pep.2025.106841_bib34","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00726-019-02787-2","article-title":"Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions","volume":"51","author":"Grassi","year":"2019","journal-title":"Amino Acids"},{"key":"10.1016\/j.pep.2025.106841_bib35","series-title":"Characterization of Protein Therapeutics Using Mass Spectrometry","first-page":"343","article-title":"Fast photochemical oxidation of proteins for structural characterization","author":"Jones","year":"2013"},{"key":"10.1016\/j.pep.2025.106841_bib37","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1021\/ac060777w","article-title":"Sequence-specific retention calculator. Algorithm for peptide retention prediction in ion-pair RP-HPLC: application to 300- and 100-\u00c5 pore size C18 sorbents","volume":"78","author":"Krokhin","year":"2006","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib38","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1021\/ac034414x","article-title":"Determination of N-Glycosylation sites and site heterogeneity in glycoproteins","volume":"75","author":"An","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/rcm.3330","article-title":"Determination of N-glycosylation sites and site heterogeneity in a monoclonal antibody by electrospray quadrupole ion-mobility time-of-flight mass spectrometry","volume":"22","author":"Olivova","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.pep.2025.106841_bib40","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1021\/ac4036857","article-title":"Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry","volume":"86","author":"Fornelli","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.dib.2015.11.031","article-title":"Glycosylation characterization of therapeutic mAbs by top- and middle-down mass spectrometry","volume":"6","author":"Tran","year":"2016","journal-title":"Data Brief"},{"key":"10.1016\/j.pep.2025.106841_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide bond structures of IgG molecules","volume":"4","author":"Liu","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.pep.2025.106841_bib43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/19420862.2016.1264550","article-title":"Physicochemical and biological characterization of SB2, a biosimilar of remicade\u00ae (Infliximab)","volume":"9","author":"Hong","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.pep.2025.106841_bib44","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.4c01882","article-title":"Analysis of the structure of 14 therapeutic antibodies using circular dichroism spectroscopy","author":"Bruque","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib45","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1002\/jps.24683","article-title":"Assessing the utility of circular dichroism and FTIR spectroscopy in monoclonal-antibody comparability studies","volume":"104","author":"Lin","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pep.2025.106841_bib46","article-title":"Conformational characterization of a novel anti-HER2 candidate antibody","volume":"14","author":"P\u00e9rez","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pep.2025.106841_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4926168","article-title":"Physicochemical and biological characterization of the proposed biosimilar tocilizumab","volume":"2017","author":"Miao","year":"2017","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pep.2025.106841_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103865","article-title":"Higher-order structure comparison of the reference and biosimilar products using spectral distance calculation on the circular dichroism spectra","volume":"114","author":"Shibata","year":"2025","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pep.2025.106841_bib49","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/glycob\/cwz045","article-title":"Updates to the symbol nomenclature for glycans guidelines","volume":"29","author":"Neelamegham","year":"2019","journal-title":"Glycobiology"},{"key":"10.1016\/j.pep.2025.106841_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2022.07.005","article-title":"Intact multi-attribute method (iMAM): a flexible tool for the analysis of monoclonal antibodies","volume":"177","author":"Carillo","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.pep.2025.106841_bib51","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jasms.2009.07.017","article-title":"Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab","volume":"20","author":"Damen","year":"2009","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.pep.2025.106841_bib52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1021\/acs.jproteome.0c00373","article-title":"Integrating intact mass analysis and middle-down mass spectrometry approaches to effectively characterize trastuzumab and adalimumab structural heterogeneity","volume":"20","author":"Zhu","year":"2021","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.pep.2025.106841_bib53","first-page":"76","article-title":"Comparing the original and biosimilar biotherapeutics of the monoclonal antibody eculizumab by intact mass measurement and middle-up mass spectrometry analysis","volume":"16","author":"Degterev","year":"2021","journal-title":"Tonkie Khimicheskie Tekhnologii"},{"key":"10.1016\/j.pep.2025.106841_bib54","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1021\/acs.analchem.8b01865","article-title":"Online hydrophobic interaction chromatography-mass spectrometry for the analysis of intact monoclonal antibodies","volume":"90","author":"Chen","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/19420862.2018.1525253","article-title":"Comprehensive characterization of monoclonal antibody by fourier transform ion cyclotron resonance mass spectrometry","volume":"11","author":"Jin","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.pep.2025.106841_bib56","doi-asserted-by":"crossref","first-page":"9347","DOI":"10.1021\/acs.analchem.3c01426","article-title":"Added value of internal fragments for top-down mass spectrometry of intact monoclonal antibodies and antibody-drug conjugates","volume":"95","author":"Wei","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib57","series-title":"Roitt's Essential Immunology","first-page":"53","article-title":"Antibodies","author":"Delves","year":"2011"},{"key":"10.1016\/j.pep.2025.106841_bib58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40259-024-00698-7","article-title":"Comparative structure activity relationship characterization of the biosimilar BAT1806\/BIIB800 to reference tocilizumab","volume":"39","author":"Liu","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.pep.2025.106841_bib59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.crimmu.2020.06.001","article-title":"Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors","volume":"1","author":"Cambay","year":"2020","journal-title":"Cur. Res. Immunol."},{"key":"10.1016\/j.pep.2025.106841_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rcm.3850","article-title":"Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data","volume":"23","author":"Alley","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.pep.2025.106841_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113218","article-title":"In-depth analysis of monoclonal antibodies using microfluidic capillary electrophoresis and native mass spectrometry","volume":"185","author":"Carillo","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.pep.2025.106841_bib62","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2015.12.045","article-title":"Intact mass analysis of monoclonal antibodies by capillary electrophoresis\u2014Mass spectrometry","volume":"1011","author":"Han","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.pep.2025.106841_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2018.00324","article-title":"Comparison of 2-Aminobenzamide, procainamide and RapiFluor-MS as derivatizing agents for high-throughput HILIC-UPLC-FLR-MS N-glycan analysis","volume":"6","author":"Keser","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib64","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1021\/acs.analchem.0c00627","article-title":"Raman spectroscopy to monitor post-translational modifications and degradation in monoclonal antibody therapeutics","volume":"92","author":"McAvan","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib65","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1021\/acs.analchem.3c00650","article-title":"Rapid estimation of size-based heterogeneity in monoclonal antibodies by machine learning-enhanced dynamic light scattering","volume":"95","author":"Shrivastava","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pep.2025.106841_bib66","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-024-00662-5","article-title":"Demonstration of physicochemical and functional similarity of the biosimilar BAT1806\/BIIB800 to reference tocilizumab","volume":"38","author":"Liu","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.pep.2025.106841_bib67","doi-asserted-by":"crossref","first-page":"22456","DOI":"10.1021\/acs.iecr.9b03432","article-title":"Relating collective diffusion, protein-protein interactions, and viscosity of highly concentrated monoclonal antibodies through dynamic light scattering","volume":"58","author":"Dear","year":"2019","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.pep.2025.106841_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113841","article-title":"Monitoring size and oligomeric-state distribution of therapeutic mAbs by NMR and DLS: Trastuzumab as a case study","volume":"195","author":"Joshi","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.pep.2025.106841_bib69","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1021\/acs.molpharmaceut.8b00210","article-title":"The effect of low ionic strength on diffusion and viscosity of monoclonal antibodies","volume":"15","author":"Pindrus","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pep.2025.106841_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/s41065-021-00205-w","article-title":"Monocytic THP-1 cells diverge significantly from their primary counterparts: a comparative examination of the chromosomal conformations and transcriptomes","volume":"158","author":"Liu","year":"2021","journal-title":"Hereditas"},{"key":"10.1016\/j.pep.2025.106841_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113169","article-title":"Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics","volume":"184","author":"Kaltashov","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.pep.2025.106841_bib72","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5414\/CP201819","article-title":"Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects","volume":"51","author":"Zhang","year":"2013","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pep.2025.106841_bib73","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pep.2025.106841_bib74","article-title":"Structural insights into IL-6 signaling inhibition by therapeutic antibodies","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.pep.2025.106841_bib75","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jcph.1795","article-title":"Differential binding of sarilumab and tocilizumab to IL-6R\u03b1 and effects of receptor occupancy on clinical parameters","volume":"61","author":"Xu","year":"2021","journal-title":"J. Clin. Pharmacol."}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592825001834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592825001834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:34:38Z","timestamp":1773326078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592825001834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":74,"alternative-id":["S1046592825001834"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2025.106841","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative biophysical and functional analysis of TCZ-UFRJ, a potential biosimilar to Actemra","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2025.106841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106841"}}